Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Review

Cellular senescence or stemness: hypoxia flips the coin

Authors: Daniel Otero-Albiol, Amancio Carnero

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

Cellular senescence is a complex physiological state whose main feature is proliferative arrest. Cellular senescence can be considered the reverse of cell immortalization and continuous tumor growth. However, cellular senescence has many physiological functions beyond being a putative tumor suppressive trait. It remains unknown whether low levels of oxygen or hypoxia, which is a feature of every tissue in the organism, modulate cellular senescence, altering its capacity to suppress the limitation of proliferation. It has been observed that the lifespan of mammalian primary cells is increased under low oxygen conditions. Additionally, hypoxia promotes self-renewal and pluripotency maintenance in adult and embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and cancer stem cells (CSCs). In this study, we discuss the role of hypoxia facilitating senescence bypass during malignant transformation and acquisition of stemness properties, which all contribute to tumor development and cancer disease aggressiveness.
Literature
1.
2.
3.
4.
5.
Rhinn M, Ritschka B, Keyes WM. Cellular senescence in development, regeneration and disease. Dev. 2019;146(20):dev151837.CrossRef
6.
7.
Carnero A, Lleonart M. The hypoxic microenvironment: A determinant of cancer stem cell evolution. Insid Cell. 2016;1(2):96–105.CrossRef
8.
Huang X, Trinh T, Aljoufi A, Broxmeyer HE. Hypoxia Signaling Pathway in Stem Cell Regulation: Good and Evil. Curr Stem Cell Reports. 2018;4(2):149–57.CrossRef
9.
Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH, Jin WL. Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies. Trends Pharmacol Sci [Internet]. 2017;38(8):669–86.PubMedCrossRef
10.
Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia Enhances the Generation of Induced Pluripotent Stem Cells. Cell Stem Cell. 2009;5(3):237–41.PubMedCrossRef
11.
Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–31.PubMedCrossRef
12.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.PubMedCrossRef
13.
14.
Beauséjour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J. 2003;22(16):4212–22.PubMedPubMedCentralCrossRef
15.
Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, et al. Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. Cancer Cell. 2018;33(2):322–336.e8.PubMedPubMedCentralCrossRef
16.
Moll UM, Zaika A. Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett. 2001;493(2-3):65–9.PubMedCrossRef
17.
Yosef R, Pilpel N, Papismadov N, Gal H, Ovadya Y, Vadai E, et al. p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling. EMBO J. 2017;36(15):2280–95.PubMedPubMedCentralCrossRef
18.
Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, Cohen S, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016;7:11190.PubMedPubMedCentralCrossRef
19.
Rodier F, Muñoz DP, Teachenor R, Chu V, Le O, Bhaumik D, et al. DNA-SCARS: Distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci. 2011;124(Pt 1):68–81.PubMedCrossRef
20.
21.
Campisi J, D’Adda Di Fagagna F. Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729–40.PubMedCrossRef
22.
23.
Chandra T, Kirschner K, Thuret JY, Pope BD, Ryba T, Newman S, et al. Independence of Repressive Histone Marks and Chromatin Compaction during Senescent Heterochromatic Layer Formation. Mol Cell. 2012;47(2):203–14.PubMedPubMedCentralCrossRef
24.
Swanson EC, Manning B, Zhang H, Lawrence JB. Higher-order unfolding of satellite heterochromatin is a consistent and early event in cell senescence. J Cell Biol. 2013;203(6):929–42.PubMedPubMedCentralCrossRef
25.
Cheng LQ, Zhang ZQ, Chen HZ, Liu DP. Epigenetic regulation in cell senescence. J Mol Med. 2017;95(12):1257–68.PubMedCrossRef
26.
Koch CM, Reck K, Shao K, Lin Q, Joussen S, Ziegler P, et al. Pluripotent stem cells escape from senescenceassociated DNA methylation changes. Genome Res. 2013;23(2):248–59.PubMedPubMedCentralCrossRef
27.
Sakaki M, Ebihara Y, Okamura K, Nakabayashi K, Igarashi A, Matsumoto K, et al. Potential roles of DNA methylation in the initiation and establishment of replicative senescence revealed by array-based methylome and transcriptome analyses. PLoS One. 2017;12(2):e0171431.PubMedPubMedCentralCrossRef
28.
Bielak-Zmijewska A, Wnuk M, Przybylska D, Grabowska W, Lewinska A, Alster O, et al. A comparison of replicative senescence and doxorubicin-induced premature senescence of vascular smooth muscle cells isolated from human aorta. Biogerontology. 2014;15(1):47–64.PubMedCrossRef
29.
30.
Chen H, Ruiz PD, McKimpson WM, Novikov L, Kitsis RN, Gamble MJ. MacroH2A1 and ATM Play Opposing Roles in Paracrine Senescence and the Senescence-Associated Secretory Phenotype. Mol Cell. 2015;59(5):719–31.PubMedPubMedCentralCrossRef
31.
Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, et al. Senescent cells develop a parp-1 and nuclear factor-κB-associated secretome (PNAS). Genes Dev. 2011;25(12):1245–61.PubMedPubMedCentralCrossRef
32.
Lo Re O, Fusilli C, Rappa F, Van Haele M, Douet J, Pindjakova J, et al. Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma. Hepatol Int. 2018;67(2):636–50.CrossRef
33.
Lo Re O, Mazza T, Giallongo S, Sanna P, Rappa F, Luong TV, et al. Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activation. Theranostics. 2020;10(2):910–24.PubMedPubMedCentralCrossRef
34.
Borghesan M, Fusilli C, Rappa F, Panebianco C, Rizzo G, Oben JA, et al. DNA Hypomethylation and histone variant macroH2A1 synergistically attenuate chemotherapy-induced senescence to promote hepatocellular carcinoma progression. Cancer Res [Internet]. 2016;76(3):594–606 [cited 2021 Jun 21], Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​26772755/​.CrossRef
35.
Lo Re O, Douet J, Buschbeck M, Fusilli C, Pazienza V, Panebianco C, et al. Histone variant macroH2A1 rewires carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells. Epigenetics [Internet]. 2018;13(8):829–45 [cited 2021 Jun 21], Available from: /pmc/articles/PMC6224214/.CrossRef
36.
37.
38.
Bereshchenko O, Lo Re O, Nikulenkov F, Flamini S, Kotaskova J, Mazza T, et al. Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome. Clin Epigenetics [Internet]. 2019;11(1) [cited 2021 Jun 21], Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​31439048/​.
39.
40.
41.
Pasque V, Radzisheuskaya A, Gillich A, Halley-Stott RP, Panamarova M, Zernicka-Goetz M, et al. Histone variant macroH2A marks embryonic differentiation in vivo and acts as an epigenetic barrier to induced pluripotency. J Cell Sci [Internet]. 2012;125(24):6094–104 [cited 2021 Jun 21]. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​23077180/​.CrossRef
42.
Khursheed M, Kolla JN, Kotapalli V, Gupta N, Gowrishankar S, Uppin SG, et al. ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. Br J Cancer. 2013;108(10):2056–62.PubMedPubMedCentralCrossRef
43.
Tordella L, Khan S, Hohmeyer A, Banito A, Klotz S, Raguz S, et al. SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer. Genes Dev. 2016;30(19):2187–98.PubMedPubMedCentralCrossRef
44.
Sarnowska E, Gratkowska DM, Sacharowski SP, Cwiek P, Tohge T, Fernie AR, et al. The Role of SWI/SNF Chromatin Remodeling Complexes in Hormone Crosstalk. Trends Plant Sci. 2016;21(7):594–608.PubMedCrossRef
45.
46.
Nacarelli T, Sell C. Targeting metabolism in cellular senescence, a role for intervention. Mol Cell Endocrinol. 2017;455:83–92.PubMedCrossRef
47.
Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis. Cell. 2015;162(3):540–51.PubMedPubMedCentralCrossRef
48.
Sullivan LB, Gui DY, Hosios AM, Bush LN, Freinkman E, Vander Heiden MG. Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells. Cell. 2015;162(3):552–63.PubMedPubMedCentralCrossRef
49.
Aird KM, Zhang R. Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett. 2015;356(2 Pt A):204–10.PubMedCrossRef
50.
51.
Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence. Cell. 2008;133(6):1006–18.PubMedCrossRef
52.
Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):978–90.PubMedPubMedCentralCrossRef
53.
Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network. Cell. 2008;133(6):1019–31.PubMedCrossRef
54.
Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479(7374):547–51.PubMedCrossRef
55.
Coppe JP, Kauser K, Campisi J, Beauséjour CM. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem. 2006;281(40):29568–74.PubMedCrossRef
56.
Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, et al. Tumour-infiltrating Gr-1 + myeloid cells antagonize senescence in cancer. Nature. 2014;515(7525):134–7.PubMedCrossRef
57.
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, et al. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell. 2016;30(4):533–47.PubMedPubMedCentralCrossRef
58.
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular Senescence: Defining a Path Forward. Cell. 2019;179(4):813–27.PubMedCrossRef
59.
60.
Narita M, Young ARJ, Arakawa S, Samarajiwa SA, Nakashima T, Yoshida S, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science. 2011;332(6032):966–70.PubMedPubMedCentralCrossRef
61.
Brusuker I, Rhodes JM, Goldman R. β-Galactosidase—An indicator of the maturational stage of mouse and human mononuclear phagocytes. J Cell Physiol. 1982;112(3):385–90.CrossRef
62.
Kopp HG, Hooper AT, Shmelkov SV, Rafii S. β-galactosidase staining on bone marrow. The osteoclast pitfall. Histol Histopathol. 2007;22(9):971–6.PubMed
63.
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363–7.PubMedPubMedCentralCrossRef
64.
Muñoz-Espín D, Cañamero M, Maraver A, Gómez-López G, Contreras J, Murillo-Cuesta S, et al. Programmed cell senescence during mammalian embryonic development. Cell. 2013;155(5):1104–18.PubMedCrossRef
65.
Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell. 2013;155(5):1119–30.PubMedCrossRef
66.
Chapman J, Fielder E, Passos JF. Mitochondrial dysfunction and cell senescence: deciphering a complex relationship. FEBS Lett. 2019;593(13):1566–79.PubMedCrossRef
67.
Dasari A, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res. 2006;66(22):10805–14.PubMedPubMedCentralCrossRef
68.
69.
Wang AS, Ong PF, Chojnowski A, Clavel C, Dreesen O. Loss of lamin B1 is a biomarker to quantify cellular senescence in photoaged skin. Sci Rep. 2017;7(1):15678.PubMedPubMedCentralCrossRef
70.
Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25(3):585–621.PubMedCrossRef
71.
de Magalhães JP, Passos JF. Stress, cell senescence and organismal ageing. Mech Ageing Dev. 2018;170:2–9.PubMedCrossRef
72.
Blasco MA. Telomeres and human disease: Ageing, cancer and beyond. Nat Rev Genet. 2005;6(8):611–22.PubMedCrossRef
73.
Martínez P, Blasco MA. Telomere-driven diseases and telomere-targeting therapies. J Cell Biol. 2017;216(4):875–87.
74.
Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41(1):181–90.PubMedCrossRef
75.
Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458–60.PubMedCrossRef
76.
Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell. 1985;43(2 Pt 1):405–13.PubMedCrossRef
77.
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Science. 1998;279(5349):349–52.PubMedCrossRef
78.
Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, RA DP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91(1):25–34.PubMedCrossRef
79.
Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 1999;96(5):701–12.PubMedCrossRef
80.
Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature. 2011;469(7328):102–6.PubMedCrossRef
81.
82.
Itahana K, Campisi J, Dimri GP. Mechanisms of cellular senescence in human and mouse cells. Biogerontology. 2004;5(1):1–10.PubMedCrossRef
83.
84.
Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15(7):397–408.PubMedCrossRef
85.
86.
D’Adda Di Fagagna F. Living on a break: Cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512–22.PubMedCrossRef
87.
Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92(6):725–34.PubMedCrossRef
88.
Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: The critical roles of p53. Oncogene. 2013;32(43):5129–43.PubMedCrossRef
89.
Pantoja C, Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene. 1999;18(35):4974–82.PubMedCrossRef
90.
Martín-Caballero J, Serrano M, Flores JM, García-Palencia P. Tumor susceptibility of p21waf1/cip1-deficient mice. Cancer Res. 2001;61(16):6234–8.PubMed
91.
Quereda V, Porlan E, Canãmero M, Dubus P, Malumbres M. An essential role for Ink4 and Cip/Kip cell-cycle inhibitors in preventing replicative stress. Cell Death Differ. 2016;23(3):430–41.PubMedCrossRef
92.
93.
Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910–7.PubMedCrossRef
94.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.PubMedPubMedCentralCrossRef
95.
Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225–9.PubMed
96.
LaPak KM, Burd CE. The molecular balancing act of p16ink4a in cancer and aging. Mol Cancer Res. 2014;12(2):167–83.PubMedCrossRef
97.
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a). Cell. 1997;88(5):593–602.PubMedCrossRef
98.
Lin AW, Barradas M, Stone JC, Van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998;12(19):3008–19.PubMedPubMedCentralCrossRef
99.
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444(7119):638–42.PubMedCrossRef
100.
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444(7119):633–7.PubMedCrossRef
101.
Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319(5868):1352–5.PubMedCrossRef
102.
Macheret M, Halazonetis TD. Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress. Nature. 2018;555(7694):112–6.PubMedPubMedCentralCrossRef
103.
Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, Van Der Horst CMAM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051):720–4.PubMedCrossRef
104.
Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, et al. Cellular senescence in naevi and immortalisation in melanoma: A role for p16? Br J Cancer. 2006;95(4):496–505.PubMedPubMedCentralCrossRef
105.
Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41(5):544–52.PubMedPubMedCentralCrossRef
106.
Dhomen N, Reis-Filho JS, da Rocha DS, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. Cancer Cell. 2009;15(4):294–303.PubMedCrossRef
107.
Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Senescence in premalignant tumours. Nature. 2005;436(7051):642.PubMedCrossRef
108.
Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725–30.PubMedPubMedCentralCrossRef
109.
Braig M, Lee S, Loddenkemper C, Rudolph C, AHFM P, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436(7051):660–5.PubMedCrossRef
110.
Denchi EL, Attwooll C, Pasini D, Helin K. Deregulated E2F Activity Induces Hyperplasia and Senescence-Like Features in the Mouse Pituitary Gland. Mol Cell Biol. 2005;25(7):2660–72.PubMedCentralCrossRef
111.
Mooi WJ. Oncogene-induced cellular senescence: Causal factor in the growth arrest of pituitary microadenomas? Horm Res. 2009;71(Suppl 2):78–81.PubMed
112.
Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A. Cellular senescence: Aging, cancer, and injury. Physiol Rev. 2019;99(2):1047–78.PubMedCrossRef
113.
Mikuła-Pietrasik J, Niklas A, Uruski P, Tykarski A, Książek K. Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells. Cell Mol Life Sci. 2020;77(2):213–29.PubMedCrossRef
114.
Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999;59(15):3761–7.PubMed
115.
Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109(3):335–46.PubMedCrossRef
116.
te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62(6):1876–83.
117.
Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63(11):2705–15.PubMed
118.
Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE, et al. p53-dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol. 2005;81(6):445–58.PubMedCrossRef
119.
Mirzayans R, Scott A, Cameron M, Murray D. Induction of Accelerated Senescence by γ Radiation in Human Solid Tumor-Derived Cell Lines Expressing Wild-Type TP53. Radiat Res. 2005;163(1):53–62.PubMedCrossRef
120.
Li M, You L, Xue J, Lu Y. Ionizing radiation-induced cellular senescence in normal, non-transformed cells and the involved DNA damage response: A mini review. Front Pharmacol. 2018;9:522.PubMedPubMedCentralCrossRef
121.
Shao L, Wang Y, Chang J, Luo Y, Meng A, Zhou D. Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury. Transl Cancer Res. 2013;2(5):397–411.PubMed
122.
Di X, Bright AT, Bellott R, Gaskins E, Robert J, Holt S, et al. A chemotherapy-associated senescence bystander effect in breast cancer cells. Cancer Biol Ther. 2008;7(6):864–72.PubMedCrossRef
123.
Saleh T, Tyutyunyk-Massey L, Gewirtz DA. Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Res. 2019;79(6):1044–6.PubMedCrossRef
124.
125.
Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S. Hypoxia-induced dedifferentiation of tumor cells - A mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol. 2005;16(4-5):554–63.PubMedCrossRef
126.
Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011;208(13):2641–55.PubMedPubMedCentralCrossRef
127.
Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, et al. Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis-initiating cells in prostate cancer. FASEB J. 2015;29(8):3141–50.PubMedCrossRef
128.
Hofstetter CP, Burkhardt JK, Shin BJ, Gürsel DB, Mubita L, Gorrepati R, et al. Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS One. 2012;7(1):e30059.PubMedPubMedCentralCrossRef
129.
Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11(3):298–300.PubMedCrossRef
130.
131.
132.
Cadet J, Richard WJ. DNA base damage by reactive oxygen species, oxidizing agents, and UV radiation. Cold Spring Harb Perspect Biol. 2013;5(2):a012559.PubMedPubMedCentralCrossRef
133.
Von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27(7):339–44.CrossRef
134.
Passos JF, Nelson G, Wang C, Richter T, Simillion C, Proctor CJ, et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol. 2010;6:347.PubMedPubMedCentralCrossRef
135.
136.
Höhn A, Jung T, Grune T. Pathophysiological importance of aggregated damaged proteins. Free Radic Biol Med. 2014;71:70–89.PubMedCrossRef
137.
Zhang YG, Wang L, Kaifu T, Li J, Li X, Li L. Featured Article: Accelerated decline of physical strength in peroxiredoxin-3 knockout mice. Exp Biol Med. 2016;241(13):1395–400.CrossRef
138.
139.
Picot CR, Perichon M, Cintrat JC, Friguet B, Petropoulos I. The peptide methionine sulfoxide reductases, MsrA and MsrB (hCBS-1), are downregulated during replicative senescence of human WI-38 fibroblasts. FEBS Lett. 2004;558(1-3):74–8.PubMedCrossRef
140.
Liao N, Shi Y, Zhang C, Zheng Y, Wang Y, Zhao B, et al. Antioxidants inhibit cell senescence and preserve stemness of adipose tissue-derived stem cells by reducing ROS generation during long-term in vitro expansion. Stem Cell Res Ther. 2019;10(1):306.PubMedPubMedCentralCrossRef
141.
Kornienko JS, Smirnova IS, Pugovkina NA, Ivanova JS, Shilina MA, Grinchuk TM, et al. High doses of synthetic antioxidants induce premature senescence in cultivated mesenchymal stem cells. Sci Rep. 2019;9(1):1296.PubMedPubMedCentralCrossRef
142.
143.
Pérez VI, Van Remmen H, Bokov A, Epstein CJ, Vijg J, Richardson A. The overexpression of major antioxidant enzymes does not extend the lifespan of mice. Aging Cell. 2009;1790(10):1005–14.
144.
Dolivo D, Hernandez S, Dominko T. Cellular lifespan and senescence: a complex balance between multiple cellular pathways. Insid Cell. 2016;1(1):36–47.CrossRef
145.
146.
147.
Vaupel P, Kallinowski F, Okunieff P. Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment of Human Tumors: A Review. Cancer Res. 1989;49(23):6449–65.PubMed
148.
Carreau A, Hafny-Rahbi BE, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med [Internet]. 2011;15(6):1239–53 [cited 2021 Apr 12], Available from: /pmc/articles/PMC4373326/.CrossRef
149.
Pouyssegur J, López-Barneo J. Hypoxia in health and disease. Mol Asp Med. 2016;47–48:1–2.CrossRef
150.
Lopez-Barneo J. Oxygen-sensing by ion channels and the regulation of cellular functions. Trends Neurosci. 1996;19(10):435–40.PubMedCrossRef
151.
152.
153.
154.
Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15(7):1312–4.PubMedCrossRef
155.
Fandrey J, Gorr TA, Gassmann M. Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res. 2006;71(4):642–51.PubMedCrossRef
156.
157.
Kaelin WG, Ratcliffe PJ. Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway. Mol Cell. 2008;30(4):393–402.PubMedCrossRef
158.
Franke K, Gassmann M, Wielockx B. Erythrocytosis: The HIF pathway in control. Blood. 2013;122(7):1122–8.PubMedCrossRef
159.
Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third α- class hypoxia inducible factor subunit, HIF3α. Gene Expr. 1998;7(3):205–13.PubMed
160.
Packer L, Fuehr K. Low oxygen concentration extends the lifespan of cultured human diploid cells [13]. Nature. 1977;267(5610):423–5.PubMedCrossRef
161.
Saito H, Hammond AT, Moses RE. The effect of low oxygen tension on the in vitro-replicative life span of human diploid fibroblast cells and their transformed derivatives. Exp Cell Res. 1995;217(2):272–9.PubMedCrossRef
162.
Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol. 2003;5(8):741–7.PubMedPubMedCentralCrossRef
163.
Betts DH, Perrault SD, King WA. Low oxygen delays fibroblast senescence despite shorter telomeres. Biogerontology. 2008;9(1):19–31.PubMedCrossRef
164.
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF). Cell. 1997;91(5):649–59.PubMedCrossRef
165.
Wright WE, Shay JW. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat Med. 2000;6(8):849–51.PubMedCrossRef
166.
Patrick A, Seluanov M, Hwang C, Tam J, Khan T, Morgenstern A, et al. Sensitivity of primary fibroblasts in culture to atmospheric oxygen does not correlate with species lifespan. Aging (Albany NY) [Internet]. 2016;8(5):841–7 [cited 2021 Mar 25], Available from: /pmc/articles/PMC4931838/.
167.
Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005;65(1):177–85.PubMedCrossRef
168.
Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood. 2011;117(2):459–69.PubMedCrossRef
169.
Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity. Cancer Cell. 2007;11(4):335–47.PubMedPubMedCentralCrossRef
170.
Bell EL, Klimova TA, Eisenbart J, Schumacker PT, Chandel NS. Mitochondrial Reactive Oxygen Species Trigger Hypoxia-Inducible Factor-Dependent Extension of the Replicative Life Span during Hypoxia. Mol Cell Biol. 2007;27(16):5737–45.PubMedPubMedCentralCrossRef
171.
172.
Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A. 2012;109(33):13314–8.PubMedPubMedCentralCrossRef
173.
Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004;23(9):1949–56.PubMedPubMedCentralCrossRef
174.
Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV. Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression. J Biol Chem. 2001;276(11):7919–26.PubMedCrossRef
175.
Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-Inducible Factor 1 Is Essential for Cell Cycle Arrest during Hypoxia. Mol Cell Biol. 2003;23(1):359–69.PubMedPubMedCentralCrossRef
176.
Hammer S, To KKW, Yoo YG, Koshiji M, Huang LE. Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle. 2007;6(15):1919–26.PubMedCrossRef
177.
178.
Young AP, Schisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008;10(3):361–9.PubMedCrossRef
179.
Wang W, Wang D, Li H. Initiation of premature senescence by Bcl-2 in hypoxic condition. Int J Clin Exp Pathol. 2014;7(5):2446–53.PubMedPubMedCentral
180.
Webster WS, Abela D. The effect of hypoxia in development. Birth Defects Res C Embryo Today Rev. 2007;81(3):215–28.CrossRef
181.
182.
183.
184.
Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell. 2010;7(2):150–61.PubMedCrossRef
185.
Huang G, Ye S, Zhou X, Liu D, Ying QL. Molecular basis of embryonic stem cell self-renewal: From signaling pathways to pluripotency network. Cell Mol Life Sci. 2015;72(9):1741–57.PubMedPubMedCentralCrossRef
186.
Danet GH, Pan Y, Luongo JL, Bonnet DA, Simon MC. Expansion of human SCID-repopulating cells under hypoxic conditions. J Clin Invest. 2003;112(1):126–35.PubMedPubMedCentralCrossRef
187.
188.
Morrison SJ, Csete M, Groves AK, Melega W, Wold B, Anderson DJ. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J Neurosci. 2000;20(19):7370–6.PubMedPubMedCentralCrossRef
189.
190.
Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 2006;126(4):663–76.PubMedCrossRef
191.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell. 2007;131(5):861–72.PubMedCrossRef
192.
Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26(7):795–7.PubMedPubMedCentralCrossRef
193.
Okita K, Hong H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc. 2010;5(3):418–28.PubMedCrossRef
194.
Sugimoto K, Matsuura T, Nakazono A, Igawa K, Yamada S, Hayashi Y. Effects of hypoxia inducible factors on pluripotency in human iPS cells. Microsc Res Tech. 2018;81(7):749–54.PubMedCrossRef
195.
Mathieu J, Zhou W, Xing Y, Sperber H, Ferreccio A, Agoston Z, et al. Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency. Cell Stem Cell. 2014;14(5):592–605.PubMedPubMedCentralCrossRef
196.
Prigione A, Rohwer N, Hoffmann S, Mlody B, Drews K, Bukowiecki R, et al. HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2. Stem Cells. 2014;32(2):364–76.PubMedPubMedCentralCrossRef
197.
Banito A, Rashid ST, Acosta JC, De Li S, Pereira CF, Geti I, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009;23(18):2134–9.PubMedPubMedCentralCrossRef
198.
Li H, Collado M, Villasante A, Strati K, Ortega S, Cãamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009;460(7259):1136–9.PubMedPubMedCentralCrossRef
199.
Mosteiro L, Pantoja C, Alcazar N, Marión RM, Chondronasiou D, Rovira M, et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science (80- ). 2016;354(6315):aaf4445.CrossRef
200.
Mosteiro L, Pantoja C, de Martino A, Serrano M. Senescence promotes in vivo reprogramming through p16 INK4a and IL-6. Aging Cell. 2018;17(2):e12711.CrossRef
201.
Chiche A, Le Roux I, von Joest M, Sakai H, Aguín SB, Cazin C, et al. Injury-Induced Senescence Enables In Vivo Reprogramming in Skeletal Muscle. Cell Stem Cell. 2017;20(3):407–414.e4.PubMedCrossRef
202.
Ocampo A, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, Hishida T, et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell. 2016;167(7):1719–1733.e12.PubMedPubMedCentralCrossRef
203.
204.
Ritschka B, Storer M, Mas A, Heinzmann F, Ortells MC, Morton JP, et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 2017;31(2):172–83.PubMedPubMedCentralCrossRef
205.
206.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.PubMedPubMedCentralCrossRef
207.
208.
Junttila MR, De Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–54.PubMedCrossRef
209.
Brurberg KG, Thuen M, Ruud E-BM, Rofstad EK. Fluctuations in p O 2 in Irradiated Human Melanoma Xenografts. Radiat Res. 2006;165(1):16–25.PubMedCrossRef
210.
Bennewith KL, Durand RE. Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res. 2004;64(17):6183–9.PubMedCrossRef
211.
212.
Triana-Martínez F, Loza MI, Domínguez E. Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy. Cells. 2020;9(2):346.PubMedCentralCrossRef
213.
214.
van Vliet T, Varela-Eirin M, Wang B, Borghesan M, Brandenburg SM, Franzin R, et al. Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression. Mol Cell. 2021;81(9):2041–52.PubMedCrossRef
215.
Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012;109(8):2784–9.PubMedPubMedCentralCrossRef
216.
Iriondo O, Rábano M, Domenici G, Carlevaris O, López-Ruiz JA, Zabalza I, et al. Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions. Oncotarget. 2015;6(31):31721–39.PubMedPubMedCentralCrossRef
217.
Bhagat M, Palanichamy JK, Ramalingam P, Mudassir M, Irshad K, Chosdol K, et al. HIF-2α mediates a marked increase in migration and stemness characteristics in a subset of glioma cells under hypoxia by activating an Oct-4/Sox-2-Mena (INV) axis. Int J Biochem Cell Biol. 2016;74:60–71.PubMedCrossRef
218.
Johansson E, Grassi ES, Pantazopoulou V, Tong B, Lindgren D, Berg TJ, et al. CD44 Interacts with HIF-2α to Modulate the Hypoxic Phenotype of Perinecrotic and Perivascular Glioma Cells. Cell Rep. 2017;20(7):1641–53.PubMedCrossRef
219.
Das B, Pal B, Bhuyan R, Li H, Sarma A, Gayan S, et al. MYC Regulates the HIF2a Stemness Pathway via Nanog and Sox2 to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells. Cancer Res. 2019;79(16):4015–25.PubMedPubMedCentralCrossRef
220.
Wu L, Yu H, Zhao Y, Zhang C, Wang J, Yue X, et al. HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells. Oncotarget. 2015;6(6):4406–17.PubMedPubMedCentralCrossRef
221.
222.
Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 2006;66(5):2725–31.PubMedCrossRef
223.
Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene. 2008;27(55):6958–69.PubMedCrossRef
224.
Wang T, Gilkes DM, Takano N, Xiang L, Luo W, Bishop CJ, et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci U S A. 2014;111(31):E3234–42.PubMedPubMedCentralCrossRef
225.
226.
Easwaran H, Tsai HC, Baylin SB. Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance. Mol Cell. 2014;54(5):716–27.PubMedPubMedCentralCrossRef
227.
228.
Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1: Interaction between H-ras and hypoxia. J Biol Chem. 2001;276(12):9519–25.PubMedCrossRef
229.
Mimura I, Nangaku M, Kanki Y, Tsutsumi S, Inoue T, Kohro T, et al. Dynamic Change of Chromatin Conformation in Response to Hypoxia Enhances the Expression of GLUT3 (SLC2A3) by Cooperative Interaction of Hypoxia-Inducible Factor 1 and KDM3A. Mol Cell Biol. 2012;32(15):3018–32.PubMedPubMedCentralCrossRef
230.
Shibuya K, Okada M, Suzuki S, Seino M, Seino S, Takeda H, et al. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget. 2015;6(2):651–61.PubMedCrossRef
231.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930–5.PubMedPubMedCentralCrossRef
232.
Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, et al. Interplay between HDAC3 and WDR5 Is Essential for Hypoxia-Induced Epithelial-Mesenchymal Transition. Mol Cell. 2011;43(5):811–22.PubMedCrossRef
233.
Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, et al. A MicroRNA Signature of Hypoxia. Mol Cell Biol. 2007;27(5):1859–67.PubMedPubMedCentralCrossRef
234.
Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One. 2012;7(6):e39520.PubMedPubMedCentralCrossRef
235.
Ferraro A, Kontos CK, Boni T, Bantounas I, Siakouli D, Kosmidou V, et al. Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGB44-PCDC4) as predictor of metastatic tumor potential. Epigenetics. 2014;9(1):129–41.PubMedCrossRef
236.
Van Den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, et al. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014;5:5203.PubMedCrossRef
237.
Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, et al. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217-and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget. 2016;7(40):64527–42.PubMedPubMedCentralCrossRef
Metadata
Title
Cellular senescence or stemness: hypoxia flips the coin
Authors
Daniel Otero-Albiol
Amancio Carnero
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02035-0

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue

Research

BUB1 drives the occurrence and development of bladder cancer by mediating the STAT3 signaling pathway

Research

Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells

Correction

Correction to: Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway

Review

Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis

Retraction Note

Retraction Note: MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/β-catenin signaling pathway by downregulating LHX2

Research

Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits